SCHEMBL10005991

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)c1ccc(CN)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)[C@@H](C)CC

nearest known ligand 0.58

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	KISS1R	Q969F8	6/20	0.58

▸	NPY4R	P50391	13/20	0.57

▸	NPY5R	Q15761	8/20	0.57

▸	NPY1R	P25929	8/20	0.57

▸	NPY2R	P49146	5/20	0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL10005986	0.98	NPY4R (0.59)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10005999	0.98	NPY4R (0.59)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10005969	0.98	NPY4R (0.59)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10006003	0.98	NPY4R (0.59)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10005993	0.97	NPY4R (0.58)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10006027	0.97	NPY4R (0.58)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10005978	0.96	NPY4R (0.57)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10005998	0.96	TFPI (0.57)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10006025	0.96	NPY4R (0.57)	KISS1RNPY4RNPY5RNPY1RNPY2R
SCHEMBL10005974	0.96	NPY4R (0.57)	KISS1RNPY4RNPY5RNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9260500-B2	Peptide and use thereof	TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)	2016-02-16	—	—	US	disclosed
US-20120172293-A1	PEPTIDE AND USE THEREOF	TAKEDA PHARMACEUTICAL COMPANY LIMITED	2012-07-05	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120172293-A1	PEPTIDE AND USE THEREOF	GLP1R, GIPR, SCTR	KISS1R 88/4885NPY4R 4/4885NPY5R 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.